Ignite Creation Date:
2024-05-06 @ 3:19 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04596670
Status:
RECRUITING
Last Update Posted:
2023-11-29
First Post:
2020-10-13
Brief Title:
68Ga-ICAM-1pep PETCT in Cancer Patients
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
68Ga-ICAM-1pep PETCT Imaging of Tumor Responses to Radiotherapy in Cancer Patients
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label positron emission tomographycomputed tomography PETCT study to investigate the clinical predictive value of 68Ga-ICAM-1pep in metastatic cancer patients receiving radiotherapy A single dose of 296 MBqkg body weight of 68Ga-ICAM-1pep will be injected intravenously The visual and semiquantitative methods will be used to assess the PETCT images
Detailed Description:
Radiotherapy has a systemic inhibitory effect on non-irradiated lesions abscopal effect in addition to local antitumor effects and currently no biomarkers are used for the prediction of the abscopal effect of radiotherapy in standard clinical practice Our recent preclinical studies identified ICAM-1 as a potential predictive biomarker for the radiotherapy-induced abscopal effect In this clinical trial we aim to investigate whether the ICAM-1-targeting radiotracer 68Ga-ICAM-1pep could be used for PET imaging of tumor responses to radiotherapy in cancer patients PETCT imaging of 68Ga-ICAM-1pep will be performed in patients before and after radiotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None